Filters
Custom request?
Type
Production region
Qualifications
Country of origin
Sermorelin API Manufacturers & Suppliers
3 verified results
All Sermorelin data. Full access. Full negotiation power
Commercial-scale Suppliers
Employees: 10+
All certificates
All certificates
Employees: 250+
All certificates
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Sermorelin | CAS No: 86168-78-7 | GMP-certified suppliers
A medication that supports treatment of growth disorders linked to dwarfism and helps prevent HIV‑associated weight loss by promoting healthy anabolic balance.
Therapeutic categories
Primary indications
- For the treatment of dwarfism, prevention of HIV-induced weight loss
Product Snapshot
- Injectable peptide supplied as an intravenous powder-for-solution formulation
- Its primary uses relate to managing growth hormone deficiency–associated dwarfism and mitigating HIV‑associated weight loss
- It was previously approved in major markets but has since been withdrawn from regulatory use
Clinical Overview
Clinically, sermorelin has been used for the evaluation and treatment of pediatric growth hormone deficiency and growth failure. It has also been described for prevention of HIV‑associated weight loss where stimulation of endogenous growth hormone secretion may provide anabolic support. Geref is a commonly cited reference product. Regulatory status varies by jurisdiction, and some historical approvals have been withdrawn.
Pharmacologically, sermorelin increases circulating growth hormone concentrations by stimulating physiologic release from the anterior pituitary. As a truncated analogue of native GHRH, it exhibits similar receptor affinity and downstream signaling, leading to pulsatile growth hormone secretion and secondary increases in insulin‑like growth factor 1.
Mechanistically, the peptide binds the GHRH receptor on somatotroph cells, activating adenylate cyclase and cyclic AMP pathways. This activation promotes synthesis and exocytosis of growth hormone while preserving endogenous feedback control.
ADME characteristics reflect those of small peptides. Absorption is via parenteral administration, followed by rapid distribution and enzymatic degradation by peptidases. The circulating half‑life is short, and elimination occurs primarily through metabolic breakdown rather than renal excretion of intact peptide. Sermorelin is not known to accumulate with repeated dosing.
Safety considerations include transient injection‑site reactions, facial flushing, and mild gastrointestinal effects. Excessive growth hormone stimulation may theoretically contribute to glucose intolerance or edema, although physiologic feedback limits sustained elevations. Use is contraindicated in individuals with known hypersensitivity to peptide components or in settings where growth hormone stimulation is inappropriate.
For API procurement, sourcing should prioritize manufacturers with robust peptide synthesis controls, validated impurity characterization, and compliance with current GMP to ensure consistency in sequence integrity, acetate content, and sterility or endotoxin limits where applicable.
Identification & chemistry
| Generic name | Sermorelin |
|---|---|
| Molecule type | Biotech |
| CAS | 86168-78-7 |
| UNII | 89243S03TE |
| DrugBank ID | DB00010 |
Pharmacology
| Summary | Sermorelin is a synthetic analog of growth hormone–releasing factor that activates the growth hormone–releasing hormone receptor on pituitary somatotrophs. This interaction promotes physiologic growth hormone secretion, increasing circulating GH levels. Its therapeutic intent is to address conditions associated with inadequate endogenous growth hormone production or catabolic weight loss. |
|---|---|
| Mechanism of action | Sermorelin binds to the growth hormone releasing hormone receptor and mimics native GRF in its ability to stimulate growth hormone secretion. |
| Pharmacodynamics | Sermorelin is used in the treatment of children with growth hormone deficiency or growth failure. Geref increases plasma growth hormone (GH) concentration by stimulating the pituitary gland to release GH. Geref is similar to the full-length native hormone (44 residues) in its ability to stimulate GH secretion in humans. |
Targets
| Target | Organism | Actions |
|---|---|---|
| Growth hormone-releasing hormone receptor | Humans | agonist |
ADME / PK
| Half-life | 11-12 min |
|---|
Formulation & handling
- Peptide API typically supplied as a lyophilized powder requiring reconstitution to a sterile aqueous solution for intravenous administration.
- Sensitive to temperature and proteolytic degradation; requires cold‑chain handling and protection from repeated freeze–thaw.
- Formulation development focuses on maintaining peptide stability (pH control, suitable buffers) and minimizing adsorption to container surfaces.
Regulatory status
Supply Chain
| Supply chain summary | Sermorelin appears to have a single identified originator manufacturer, with additional packagers supporting downstream distribution. Branded product presence is primarily documented in the United States, with limited evidence of broad EU availability. Patent expiry for this peptide suggests that generic or non‑branded versions are already feasible and may contribute to a diversified supply chain. |
|---|
Sermorelin is a type of Corticotropic hormones
Corticotropic hormones, a subcategory of pharmaceutical active pharmaceutical ingredients (APIs), play a crucial role in regulating various physiological processes in the human body. These hormones are primarily secreted by the anterior pituitary gland and are responsible for controlling the production and release of glucocorticoids, which are essential for maintaining homeostasis and managing stress.
Corticotropic hormones are mainly comprised of adrenocorticotropic hormone (ACTH), which stimulates the adrenal glands to produce cortisol, a vital stress hormone. This hormone influences multiple bodily functions, including metabolism, immune response, and blood pressure regulation. Additionally, corticotropic hormones also play a significant role in controlling inflammation and allergic reactions.
Pharmaceutical companies often utilize corticotropic hormones as APIs to develop medications that can effectively regulate adrenal function. These medications are commonly prescribed for individuals suffering from conditions such as adrenal insufficiency, autoimmune disorders, and certain types of cancer.
By harnessing the therapeutic potential of corticotropic hormones, pharmaceutical manufacturers can develop drugs that provide relief to patients experiencing adrenal dysfunction. These APIs can be formulated into various dosage forms, including tablets, injections, and topical creams, to cater to different patient needs.
Overall, corticotropic hormones are vital pharmaceutical APIs that offer immense potential in managing adrenal disorders and related conditions. Through continued research and development, these APIs have the potential to revolutionize the treatment landscape and improve the quality of life for countless individuals worldwide.
Sermorelin (Corticotropic hormones), classified under Hormonal Agents
Hormonal agents are a prominent category of pharmaceutical active pharmaceutical ingredients (APIs) widely used in the medical field. These substances play a crucial role in regulating and modulating hormonal functions within the body. Hormonal agents are designed to mimic or manipulate the effects of naturally occurring hormones, allowing healthcare professionals to treat various endocrine disorders and hormonal imbalances.
Hormonal agents are commonly employed in the treatment of conditions such as hypothyroidism, hyperthyroidism, diabetes, and hormonal cancers. These APIs work by interacting with specific hormone receptors, either by stimulating or inhibiting their activity, to restore the balance of hormones in the body. They can be administered orally, intravenously, or through other routes depending on the specific medication and patient needs.
Pharmaceutical companies employ rigorous manufacturing processes and quality control measures to ensure the purity, potency, and safety of hormonal agent APIs. These APIs are synthesized using chemical or biotechnological methods, often starting from natural hormone sources or through recombinant DNA technology. Stringent regulatory guidelines are in place to guarantee the efficacy and safety of hormonal agent APIs, ensuring that patients receive high-quality medications.
As the demand for hormone-related therapies continues to grow, ongoing research and development efforts focus on enhancing the effectiveness and reducing the side effects of hormonal agent APIs. This includes the exploration of novel delivery systems, advanced formulations, and targeted drug delivery methods. By continuously advancing our understanding and capabilities in hormonal agents, the medical community can improve patient outcomes and quality of life for individuals with hormonal disorders.
Sermorelin API manufacturers & distributors
Compare qualified Sermorelin API suppliers worldwide. We currently have 3 companies offering Sermorelin API, with manufacturing taking place in 1 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| Apino Pharma Co., Ltd. | Producer | China | China | BSE/TSE, CoA, MSDS | 229 products |
| Attix Pharmaceuticals | Distributor | United States | China | CoA, FDA, MSDS | 7 products |
| Hangzhou Thinheal Pharma-... | Producer | China | China | BSE/TSE, CoA, GMP, MSDS | 17 products |
When sending a request, specify which Sermorelin API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Sermorelin API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
Frequently asked questions about Sermorelin API
Sourcing
What matters most when sourcing GMP-grade Sermorelin?
Which documents are typically required when sourcing Sermorelin API?
Which manufacturers are known to produce Sermorelin API?
How can I request quotes for Sermorelin API from GMP suppliers?
Is a GMP audit report available for Sermorelin manufacturers?
How many suppliers offer Sermorelin API on Pharmaoffer?
Which countries are known to manufacture Sermorelin API?
Which certifications do suppliers of Sermorelin usually hold?
Technical
What is Sermorelin (CAS 86168-78-7) used for?
Which therapeutic class does Sermorelin fall into?
What conditions is Sermorelin mainly prescribed for?
How does Sermorelin work?
What should someone know about the safety or toxicity profile of Sermorelin?
What are important formulation and handling considerations for Sermorelin as an API?
Is Sermorelin a biotech?
Are there special stability concerns for oral Sermorelin?
Pharmaoffer
How does Pharmaoffer’s Smart Sourcing Service help with Sermorelin procurement?
Is Sermorelin included in the PRO Data Insights coverage?
Where can I access the API market report for Sermorelin?
